This study aimed to perform a comprehensive, retrospective evaluation of PD-L1 expression based on IHC assays with three PD-L1 antibodies (SP142, SP263, and 22C3) in tumors of patients with breast cancer. This evidence concerns the gene CD274 and breast carcinoma.